Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P23229

UPID:
ITA6_HUMAN

ALTERNATIVE NAMES:
CD49 antigen-like family member F; VLA-6

ALTERNATIVE UPACC:
P23229; B2RMU9; B4DG69; B4DKB8; C4AM96; G5E9H1; Q08443; Q0MRC7; Q14646; Q16508; Q53RX7; Q59HB7; Q86VL6; Q9UCT1; Q9UN03

BACKGROUND:
Integrin alpha-6 functions as a crucial receptor for laminin, facilitating essential interactions in platelets, oocytes, and epithelial cells. Its roles in sperm-egg fusion, structural support in epithelial cells, and signaling through binding with NRG1, IGF1, and IGF2, highlight its multifaceted importance in cellular physiology and development. The protein's alternative names, CD49 antigen-like family member F and VLA-6, reflect its diverse functions and interactions.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Integrin alpha-6 could open doors to potential therapeutic strategies. Its involvement in Epidermolysis bullosa, junctional 6, with pyloric atresia, a disease marked by severe skin blistering and fragility, points to its critical role in maintaining skin integrity. Targeting Integrin alpha-6 pathways may offer new avenues for treating this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.